Elastosis perforans serpiginosa induced by penicillamine
- 1 May 1977
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 113 (5) , 630-635
- https://doi.org/10.1001/archderm.113.5.630
Abstract
A patient with Wilson disease, under prolonged treatment with penicillamine, developed lesions of elastosis perforans serpiginosa (EPS). Examination of biopsy specimens by light microscopy revealed the characteristic changes of EPS. Examination by transmission electron microscopy revealed structural changes in the elastic fibers not previously described. The appearance of the lesions by scanning electron microscopy is described for the first time. Penicillamine induced EPS may be morphologically distinct from the idiopathic form.This publication has 7 references indexed in Scilit:
- Penicillamine-induced skin lesions. A possible example of human lathyrismArchives of Dermatology, 1967
- CARDIOVASCULAR STUDIES ON COPPER-DEFICIENT SWINE .10. FINE STRUCTURE OF DEFECTIVE ELASTIC MEMBRANES1967
- Elastolysis and Giant Cell Reaction against Disintegrated Elastic FibresNature, 1965
- BIOSYNTHESIS OF ELASTIN CROSS-LINKS - EFFECT OF COPPER DEFICIENCY AND A LATHYROGEN1965
- Preliminary Observations on Senile Elastosis Using the Electron Microscope**From the Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland.National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare.Journal of Investigative Dermatology, 1963
- STUDIES ON COPPER METABOLISM .32. CARDIOVASCULAR LESIONS IN COPPER-DEFICIENT SWINE1962
- Electron Microscopic Observations on the Lesion of Elastosis Perforans Serpiginosa**From the Medical and Dermatology Services, Massachusetts General Hospital, and the Departments of Medicine and Dermatology, Harvard Medical School, Boston, Massachusetts.This is Publication No. 274 from the Robert W. Lovett Memorial Unit for the Study of Crippling Disease. Support of these investigations has been received in large part from the National Institute of Arthritis and Metabolic Diseases, U.S.P.H.S., (Grants #A10647 and A-3785), and the Eli Lilly Company.Journal of Investigative Dermatology, 1960